FY2026 EPS Forecast for Dyadic International Cut by Analyst

Dyadic International Inc. (NASDAQ:DYAI) – Zacks Research reduced their FY2026 EPS estimates for shares of Dyadic International in a research report issued to clients and investors on Friday, August 14th. Zacks Research analyst J. Vandermosten now anticipates that the biotechnology company will post earnings per share of ($0.15) for the year, down from their previous estimate of $0.13. The consensus estimate for Dyadic International’s current full-year earnings is $0.13 per share.

Dyadic International (NASDAQ:DYAI) last posted its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). Dyadic International had a negative return on equity of 2,920.31% and a negative net margin of 201.43%.The company had revenue of $0.96 million for the quarter, compared to the consensus estimate of $1.02 million.

Separately, Weiss Ratings raised Dyadic International from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 12th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Dyadic International has an average rating of “Hold” and an average target price of $3.00.

Dyadic International Stock Down 3.3%

DYAI opened at $0.74 on Thursday. The stock has a market cap of $26.93 million, a PE ratio of -3.21 and a beta of 1.12. The company has a quick ratio of 1.65, a current ratio of 1.65 and a debt-to-equity ratio of 4.08. Dyadic International has a 52 week low of $0.65 and a 52 week high of $1.60. The business’s fifty day simple moving average is $0.97 and its 200 day simple moving average is $0.86.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Bank of America Corp DE lifted its holdings in shares of Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 26,965 shares during the last quarter. Landscape Capital Management L.L.C. bought a new position in shares of Dyadic International during the 3rd quarter valued at $190,000. Marathon Capital Management grew its holdings in shares of Dyadic International by 142.9% during the 4th quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 50,000 shares during the last quarter. Geode Capital Management LLC raised its position in Dyadic International by 13.7% in the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 36,266 shares during the period. Finally, BlackRock Inc. purchased a new position in Dyadic International in the 2nd quarter worth $177,000. 27.95% of the stock is owned by hedge funds and other institutional investors.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.